The Monoclonal Antibodies market was estimated at US$ 95.4 billion in 2020 and is expected to hit around US$ 150.4 billion by 2030, growing at a CAGR of 15.7% from 2021 to 2030.
The Monoclonal Antibodies market was estimated at US$ 95.4 billion in 2020 and is expected to hit around US$ 150.4 billion by 2030, growing at a CAGR of 15.7% from 2021 to 2030.
Growth Factors
Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period.
Increasing demand for personalized medicine is a vital factor responsible for the increasing development of therapeutic antibodies to provide targeted therapies as every individual responds in a different manner to a particular treatment. Moreover, related benefits of using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production, are contributing to significant market growth.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38040
In addition, the government initiatives to enable the cost-effective production of mAbs are anticipated to propel the emergence of this sector over the forecast period. For instance, the biomanufacturing initiative by the National Institute of Standards and Technology in the U.S. provides scientifically sound regulatory guidelines to ensure effective and safe manufacturing of protein therapeutics and to support biopharmaceutical manufacturers in offering low-cost and high-quality protein drugs across the globe.
Report Highlights
mAbs can be produced in vivo or in vitro. Both techniques are widely accepted and commercially used. In vivo technology is cost-effective as compared to in vitro production techniques and is preferred for the high concentration of mAbs obtained through this method.
However, the availability of several in vitro methods is expected to hamper the adoption of in vivo production techniques in the coming years. The associated benefits of employing in vitro methods for antibody generation, including time efficiency, economic viability, and large-scale production, are anticipated to fuel the segment growth over the forecast period.
Therapeutic mAbs find wide applications in cancer treatment. Moreover, the surging incidence of cancer is the key contributing factor for the growth of the mAbs vertical. These have proven to be the best treatment alternative for cancer as compared to drugs and chemotherapy due to the minimum adverse effects associated with their use.
At present, mAbs are used in the treatment of various cancer types including non-small cell lung, brain tumor, breast, ovarian, colorectal, gastric, melanoma, Hodgkin’s lymphoma, and others. Moreover, several mAbs awaiting treatment approval are undergoing clinical trials and thus the growing drug pipeline is anticipated to provide future growth opportunities to this vertical.
Increasing adoption of mAbs as a preferred line of treatment especially in the case of cancer contributed toward the largest share of over 35.0% of the hospital end-use segment in 2020.
Increasing incidence of chronic conditions fueling treatment rate, rising healthcare expenditure level, and awareness level amongst the patient population regarding treatment alternatives are factors expected to result in the dominance of hospitals in the end-use segment during the forecast period.
North America held the maximum share in 2020 due to the presence of a well-established healthcare infrastructure. Moreover, increasing government funding for cancer research and technology development is anticipated to boost the development of therapeutic proteins over the forecast period. Government support in infection control & management, rising incidence of lifestyle-associated diseases, and the escalating population number are other important factors aiding the growth of this sector.
Key Players
Novartis AG, Pfizer, Inc, GlaxoSmithKline plc, Amgen, Inc., Merck & Co., Inc, Daiichi Sankyo Company, Ltd., Abbott, AstraZeneca, Eli Lilly, Johnson & Johnson Services, Inc., Bayer AG, Bristol Myers Squibb Co., Mylan N.V., Biogen Inc., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, Sanofi Genzyme, and F. Hoffmann-La Roche Ltd.
Market Segmentation
- Source Type Outlook
- Murine
- Chimeric
- Humanized
- Human
- Production Type Outlook
- In Vivo
- In Vitro
- Indication Outlook
- Cancer
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Microbial Diseases
- Others
- End-use Outlook
- Hospitals
- Research Institutes
- Others
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38040
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333